| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | 3.618 | 18.018 | 21.058 | 22.094 | 33.779 | 50.465 |
| Total Income - EUR | - | - | - | - | 3.618 | 18.018 | 21.058 | 22.094 | 33.779 | 50.465 |
| Total Expenses - EUR | - | - | - | - | 70 | 365 | 660 | 2.528 | 8.565 | 10.450 |
| Gross Profit/Loss - EUR | - | - | - | - | 3.547 | 17.654 | 20.398 | 19.566 | 25.214 | 40.015 |
| Net Profit/Loss - EUR | - | - | - | - | 3.439 | 17.152 | 19.767 | 19.016 | 24.876 | 38.501 |
| Employees | - | - | - | - | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Octamed Neuroclinic S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | 3.589 | 21.988 | 24.771 | 19.862 | 25.794 | 40.332 |
| Inventories | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | 351 | 18.290 | 21.020 | 15.821 | 21.588 | 33.439 |
| Cash | - | - | - | - | 3.238 | 3.698 | 3.751 | 4.041 | 4.206 | 6.892 |
| Shareholders Funds | - | - | - | - | 3.481 | 17.202 | 19.815 | 19.081 | 24.925 | 38.549 |
| Social Capital | - | - | - | - | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | 109 | 4.786 | 4.956 | 781 | 869 | 1.783 |
| Income in Advance | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Octamed Neuroclinic S.r.l.